Seeking Alpha

Infinity Pharmaceuticals (INFI -20.5%) gets slammed by cautious comments out of JPMorgan today,...

Infinity Pharmaceuticals (INFI -20.5%) gets slammed by cautious comments out of JPMorgan today, saying that investors are "growing increasingly skittish" ahead of INFI's pending presentation at June's ASCO cancer conference. The company is expected to release Phase 1 clinical safety and tolerability data for IPI-145, its experimental leukemia drug, and while the investment bank predicts "a good showing," it may not be enough to outshine Gilead (GILD -2.3%), Pharmacyclics (PCYC -2.5%) or Roche (RHHBY.OB -0.6%).
Comments (3)
  • I don't understand why ONXX, PCYC and GILD are down
    16 May 2013, 01:41 PM Reply Like
  • All of pharma is down today
    16 May 2013, 04:45 PM Reply Like
  • Alll of pharma is down today
    16 May 2013, 04:45 PM Reply Like
DJIA (DIA) S&P 500 (SPY)